Prolight Diagnostics (PRLD) investor relations material

Executive summary

• Achieved a major milestone by moving from technology verification to commercial validation, driven by strong results from a traumatic brain injury (TBI) study with BRAINBox Solutions, leading to a SEK 29 million development agreement.

• Positive patent decisions in Japan and the US further strengthened the IP position for the Psyros platform.

• Design freeze for the Psyros instrument was achieved, enabling pilot production and regulatory studies.

• Increased commercial interest and strategic partnership discussions following successful study results and industry events.

Financial highlights

• Net sales remained at 0 SEK for both Q2 and the first half of 2026, unchanged from the previous year.

• Other operating income was 2,840 TSEK in Q2 (down from 13,945 TSEK) and 4,042 TSEK for H1 (down from 15,607 TSEK), mainly from BRAINBox contributions.

• Operating loss (EBIT) improved to -8,304 TSEK in Q2 (from -15,346 TSEK) and -18,694 TSEK for H1 (from -26,281 TSEK).

• Profit after tax matched EBIT at -8,304 TSEK for Q2 and -18,694 TSEK for H1.

• Earnings per share improved to -0.69 SEK in Q2 (from -1.81 SEK) and -1.55 SEK for H1 (from -3.38 SEK).

• Cash flow from operating activities was positive at 7,766 TSEK in Q2 (vs. -4,699 TSEK) but negative at -4,874 TSEK for H1 (vs. -13,875 TSEK).

• Liquid assets at period end were 16,939 TSEK (up from 5,652 TSEK a year earlier).

Outlook and guidance

• Focus for the coming period is on validating manufacturing processes, initiating pilot production, and advancing regulatory studies.

• Strategic partnership discussions are intensifying, supported by recent positive study outcomes and increased market interest.